**Analysis:**
The earnings call for Merck & Co., Inc. for the third quarter of 2006 revealed strong performance across multiple product lines, particularly Singulair, Vytorin, and Zetia, as well as robust vaccine sales. The company raised its full-year 2006 EPS guidance, reflecting a solid quarter and year-to-date performance. Management addressed the impact of Vioxx litigation, highlighting the company's commitment to defending the cases and providing an update on the Vioxx legal defense reserve. The call also discussed the launch of Januvia, a new diabetes drug, and the potential for market adoption of Gardasil and Zostavax vaccines. Overall, the call provided positive insights into the company's performance and strategic initiatives.

**Conclusion:**
The earnings call for Merck & Co., Inc. for the third quarter of 2006 was generally positive, with strong performance across multiple product lines and an increase in full-year 2006 EPS guidance. The stock is likely to experience a positive impact in the short term due to the company's solid quarterly results and strategic initiatives.

**Rating:** 1